CL2025001091A1 - Anticuerpos vegf - Google Patents

Anticuerpos vegf

Info

Publication number
CL2025001091A1
CL2025001091A1 CL2025001091A CL2025001091A CL2025001091A1 CL 2025001091 A1 CL2025001091 A1 CL 2025001091A1 CL 2025001091 A CL2025001091 A CL 2025001091A CL 2025001091 A CL2025001091 A CL 2025001091A CL 2025001091 A1 CL2025001091 A1 CL 2025001091A1
Authority
CL
Chile
Prior art keywords
vegf antibodies
relates
vegf
antibodies
kits
Prior art date
Application number
CL2025001091A
Other languages
English (en)
Inventor
Bates David
Original Assignee
Univ Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nottingham filed Critical Univ Nottingham
Publication of CL2025001091A1 publication Critical patent/CL2025001091A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos anti-VEGF-A165b. La invención también se refiere a composiciones farmacéuticas, kits y métodos de uso en un tratamiento.
CL2025001091A 2022-10-13 2025-04-10 Anticuerpos vegf CL2025001091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2215115.3A GB202215115D0 (en) 2022-10-13 2022-10-13 VEGF antibodies

Publications (1)

Publication Number Publication Date
CL2025001091A1 true CL2025001091A1 (es) 2025-08-01

Family

ID=84818408

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001091A CL2025001091A1 (es) 2022-10-13 2025-04-10 Anticuerpos vegf

Country Status (13)

Country Link
EP (1) EP4602070A1 (es)
JP (1) JP2025533941A (es)
KR (1) KR20250088561A (es)
CN (1) CN120225554A (es)
AR (1) AR130760A1 (es)
AU (1) AU2023361530A1 (es)
CA (1) CA3268545A1 (es)
CL (1) CL2025001091A1 (es)
GB (1) GB202215115D0 (es)
IL (1) IL320094A (es)
MX (1) MX2025004285A (es)
TW (1) TW202417493A (es)
WO (1) WO2024079482A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
WO2014117053A1 (en) * 2013-01-27 2014-07-31 The Cleveland Clinic Foundation Anti-angiogenic vegf-ax isoform

Also Published As

Publication number Publication date
WO2024079482A1 (en) 2024-04-18
CA3268545A1 (en) 2024-04-18
IL320094A (en) 2025-06-01
JP2025533941A (ja) 2025-10-09
AR130760A1 (es) 2025-01-15
AU2023361530A1 (en) 2025-05-22
CN120225554A (zh) 2025-06-27
MX2025004285A (es) 2026-02-03
KR20250088561A (ko) 2025-06-17
TW202417493A (zh) 2024-05-01
GB202215115D0 (en) 2022-11-30
EP4602070A1 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
CL2024003552A1 (es) Anticuerpo anti-ccr8; método de producción; composición farmacéutica; y su uso.
MX2020013169A (es) Conjugados de camptotecina.
CR20200653A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX2020008772A (es) Conjugados de il-15, y sus usos.
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
MX2021007845A (es) Anticuerpos contra il-4ra humano y uso de los mismos.
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
EA202192606A1 (ru) Антитела к пироглутамат--амилоиду и их применение
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
MX2021016050A (es) Formulaciones transdermicas.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
EA202191666A1 (ru) Антитела к il-27 и их применение
BR112018008900A2 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.